Immunomodulating drugs

General description B cell lymphoma 3 (BCL3), an oncogene, belongs to the inhibitor of the &#954: B (I&#954:B) family. It is a nuclear protein with a transactivation domain.

Anti-BCL-3 Antibody has been tested in Western Blot, ELISA, and Immunofluorescence. Expect a band at 47.

Anti-BCL-3 Antibody has been tested in Western Blot, ELISA, and Immunofluorescence. Expect a band at 47.

Immunogen Recombinant fragment corresponding to a region within amino acids 160 and 415 of according to NP_001697 Application Suggested starting dilutions are as follows: IHC-P: 1:100-1:1000, IP: 1:100-1:500, WB: 1:500-1:3000, ChIP assay:

BCL6 (B-cell CLL/lymphoma 6) is a nuclear protein, belonging to the BTB/POZ (BR-C, ttk and bab/Pox virus and Zinc finger) domain family of transcription factors. This zinc finger transcription factor has a molecular mass of 95kDa.

Immunogen B-cell CLL/lymphoma 6 Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the

Immunogen BCL6B (AAH59404.1, 1 a.

Anti-BCL6B B-cell CLL/lymphoma 6, member B, 25ul UN 1687 6.1

General description The protein named B-cell CLL/lymphoma 7 protein family member A or BCL7A and encoded by the human gene named BCL7A is protein that interacts with SWI/SNF components (a nucleosome remodeling complex), implicating that

General description The protein encoded by this gene contains a region that is highly similar to the N-terminal segment of BCL7A protein. The BCL7A protein is encoded by the gene known to be directly involved in a three-way gene translocation in a

Immunogen B-cell CLL/lymphoma 7B Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the

Immunogen B-cell CLL/lymphoma 7B Application All Prestige Antibodies Powered by Atlas Antibodies are developed and validated by the Human Protein Atlas (HPA) project and as a result, are supported by the most extensive characterization in the